Abstract
The purpose of this review is to provide a comprehensive update on recent advances in heart transplantation in China. Despite advances in pharmacologic and device treatment of chronic heart failure, long-term morbidity and mortality remain high, and many patients progress to endstage heart failure. Heart transplantation has become standard treatment for selected patients with end-stage heart failure, though challenges still exist. However, multiple advances over the past few years will improve the survival and quality-of-life of heart transplant recipients. This article elaborates on the specific characteristics of heart transplantation in China, the current issues, development trends, and related experiences with heart transplantation in Wuhan Union Hospital.
Article PDF
Similar content being viewed by others
References
Hu SS, Gao RL, Liu LS, et al. Summary of the 2018 Report on Cardiovascular Diseases in China. Chin Cir J (Chinese), 2019,34:209–220
van der Meer P, Gaggin HK, Dec GW. ACC/AHA Versus ESC Guidelines on Heart Failure: JACC Guideline Comparison. J Am Coll Cardiol, 2019,73(21):2756–2768
Hayes DJ, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-second pediatric lung and heart-lung transplantation report-2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant, 2019,38(10):1015–1027
Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant, 2016,35(1):1–23
Wang Y, Cai J, Sun Y, et al. Extended donor criteria in heart transplantation: a retrospective study from a single Chinese institution. J Thorac Dis, 2018,10(4):2153–2165
Guglin M, Zucker MJ, Borlaug BA, et al. Evaluation for Heart Transplantation and LVAD Implantation: JACC Council Perspectives. J Am Coll Cardiol, 2020,75(12):1471–1487
Kormos RL, Cowger J, Pagani FD, et al. The Society of Thoracic Surgeons Intermacs database annual report: Evolving indications, outcomes, and scientific partnerships. J Heart Lung Transplant, 2019,38(2):114–126
Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med, 2001,345(20):1435–1443
Massad M G. Christiaan Neethling Barnard (1922- 2001). J Thorac Cardiovasc Surg, 2002,123(1):1–2
Iyer A, Gao L, Doyle A, et al. Normothermic ex vivo perfusion provides superior organ preservation and enables viability assessment of hearts from DCD donors. Am J Transplant, 2015,15(2):371–380
Dhital KK, Iyer A, Connellan M, et al. Adult heart transplantation with distant procurement and ex-vivo preservation of donor hearts after circulatory death: a case series. Lancet, 2015,385(9987):2585–2591
Boucek MM, Mashburn C, Dunn SM, et al. Pediatric heart transplantation after declaration of cardiocirculatory death. N Engl J Med, 2008,359(7):709–714
Messer S, Page A, Axell R, et al. Outcome after heart transplantation from donation after circulatorydetermined death donors. J Heart Lung Transplant, 2017,36(12):1311–1318
Kleinmahon JA, Patel SS, Auerbach SR, et al. Hearts transplanted after circulatory death in children: Analysis of the International Society for Heart and Lung Transplantation registry. Pediatr Transplant, 2017,21(8)
Chew HC, Iyer A, Connellan M, et al. Outcomes of Donation After Circulatory Death Heart Transplantation in Australia. J Am Coll Cardiol, 2019,73(12):1447–1459
Kransdorf EP, Kittleson MM, Benck LR, et al. Predicted heart mass is the optimal metric for size match in heart transplantation. J Heart Lung Transplant, 2019,38(2):156–165
Holzhauser L, Imamura T, Bassi N, et al. Increasing heart transplant donor pool by liberalization of size matching. J Heart Lung Transplant, 2019,38(11):1197–1205
Woolley AE, Singh SK, Goldberg HJ, et al. Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients. N Engl J Med, 2019,380(17):1606–1617
Radzi Y, Shezad M F, Danziger-Isakov L, et al. Using hepatitis C and B virus-infected donor organs for pediatric heart transplantation. J Thorac Cardiovasc Surg, 2019,158(2):548–553
Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant, 2010,29(8):914–956
Yamani MH, Taylor DO, Rodriguez ER, et al. Transplant vasculopathy is associated with increased AlloMap gene expression score. J Heart Lung Transplant, 2007,26(4):403–406
De Vlaminck I, Valantine HA, Snyder TM, et al. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med, 2014,6(241):241ra77
Wever-Pinzon O, Romero J, Kelesidis I, et al. Coronary computed tomography angiography for the detection of cardiac allograft vasculopathy: a meta-analysis of prospective trials. J Am Coll Cardiol, 2014,63(19):1992–2004
Wang Y, Cai J, Sun Y, et al. Extended donor criteria in heart transplantation: a retrospective study from a single Chinese institution. J Thorac Dis, 2018,10(4):2153–2165
Wu J, Zhang H, Shi X, et al. Ablation of Transcription Factor IRF4 Promotes Transplant Acceptance by Driving Allogenic CD4+ T Cell Dysfunction. Immunity, 2017,47(6):1114–1128
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Sun, Yf., Wang, Zw., Zhang, J. et al. Current Status of and Opinions on Heart Transplantation in China. CURR MED SCI 41, 841–846 (2021). https://doi.org/10.1007/s11596-021-2444-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-021-2444-9